NCM USA Bronx LLC
(917) 226-2029
461 Park Ave S 2nd Fl
New York, New York,
USA
10016-7483
NCM USA Bronx is a radiopharmaceutical company specializing manufacturing and distributing molecular imaging tracers. NCM maintains sponsored researches and has relationships with universities and hospitals to identify promising new imaging technologies.
- Year Established:
- 2010
Products & Services
-
- Radiopharmaceutical
- Isotopes
- Pet
- P.e.t.
- Fdg
- Ammonia
- Zirconium
- Nuclear Medicine
- F-18
- Imaging Tracers
- Medical Research
-
- Manufacturing
- Manufacturer
- Production
- Ion
- Av-133
- Diagnostic
- Diagnostic Imaging
- Nuclear Imaging
- Research
- Development
- M
Web Result
- NCM USA
- Press Releases NCM USA launches a new era in PET Radiopharmaceutical Manufacturing NCM USA Announces Commercial Availability of Zr-89 for Development of PET Radiopharmaceuticals Tour our up and coming state-of-the-art manufacturing facility . The radionuclides employed for imaging purposes are isotopes of radioactive elements such as uranium or iodine that produce gamma rays with high penetrating ...
- NCM USA
- Tour our up and coming state-of-the-art manufacturing facility . The radionuclides employed for imaging purposes are isotopes of radioactive elements such as uranium or iodine that produce gamma rays with high penetrating power that can be recorded by a gamma camera or scintillation detector that captures the images..> produced by the radiation. Radionuclides and carrier molecules are chosen based...
- Industry Growth
Introduction to Nuclear Medicine History of Nuclear Medicine Industry Growth PET Growth to Drive Radiopharmaceutical Industry Growth Positron emission tomography (PET) is a cutting-edge variant of radiopharmaceutical imaging. PET s high degree of sophistication allows for detailed study of an organ s metabolic activity, unlike the purely anatomical imaging modalities of computer tomography (CT...
- NCM USA
The NCM Facility NCM s Bronx facility will be a state-of-the-art hospital-PET manufacturing facility. The facility will be equipped with the most advanced PET GMP technologies to manufacture multiple radiopharmaceuticals simultaneously. This will be our key market differentiation, since current PET manufacturing facilities can only produce one or two products in their aged plants. The 10,000+ sq...
- NCM USA
- NCM s strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribution network in New York State. The American market for molecular imaging agents currently exceeds $1.3 billion annually and is expected to grow to over $3 billion by 2020. Anwer Rizvi, President & CEO, has a proven track record of developing a distribution network for PET in the United States, E...
Website Links:
Own this business?
Request to update the information
Ads by MFGpages
